received care as usual. Measures of primary outcome (metacognition), secondary outcomes (empathy, depression, insight, stigma, social functioning, symptoms and quality of life) and control variables (neurocognition, premorbid IQ) were collected at baseline (pre), directly after therapy end (post) and at 6-month follow-up. After the follow-up measurement, research assistants were unblinded in order to conduct an interview with the participants regarding their experience of the therapy. Results: Multilevel intention-to-treat and sensitivity analyses demonstrated that in both groups metacognition had improved, with no significant differences between the groups (χ2 (1)=0.435, p=.51). At 6-month follow-up, however, participants in the MERIT condition demonstrated they had continued to improve on metacognition, while scores from the control condition dipped back down (χ2 (1)=3.763, p=.05). Gains mainly seemed to be on metacognitive Self-Reflectivity (χ2 (1)=10.295, p=.001). No effects were found on secondary measures in either condition. Discussion: During this presentation, we will discuss our findings and the therapy protocol, including a discussion of the clinical relevance of the current intervention, analysis of post-therapy interviews surrounding the participant's experiences of the therapy, as well as practical limitations that were encountered during this five-year trial. Background: Relapse prevention is a major aim of any treatment for schizophrenia patients. In general, recent meta-analyses showed that one third of schizophrenia patients relapse in the first year after treatment, which corresponds with rehospitalization. Since years, study data support evidence for successful relapse prevention of psycho-educative and family therapy approaches in combination with pharmacological treatment. So far little is known about the impact of Cognitive Remediation Therapy (CRT) on relapse prevention. Methods: The purpose of this RCT was to investigate whether additional CRT could prevent relapses compared to treatment as usual (TAU) defined as pharmacological and other psychosocial treatments. The CRT approach of choice was the Integrated Neurocognitive Therapy (INT) developed in our lab. INT is a group approach consisting of 4 modules including interventions on all the neuro-and social cognitive domains, defined by the MATRICS initiative, as well as educational, emotion regulation and stress reduction tasks. In this international multicenter study, a total of 156 stabilized schizophrenia outpatients, diagnosed with DSM-IV, participated. From this sample, 71 participants of two out of eight centers could be observed during a follow-up of 1, 5 and 8 years, regarding number of relapses and days of rehospitalization. Relapses were defined as increased symptoms followed by rehospitalization. Results: One year after therapy, no marked differences between INT and TAU groups in relapse rates were evident. But during 5-and 8-year follow-up, 78% and 83% of TAU patients relapsed compared to 48% and 52% of INT patients suggesting a significant benefit of INT. TAU patients suffered from more than 2 relapses after 5 years and 2.5 relapses after 8 years. In comparison, INT patients showed 0.9 relapses after 5 and 1.4 relapses after 8 years. After the 5 years follow-up there was a highly significant difference between INT and TAU, and after the 8-years a statistical tendency favoring INT could be found. Regarding the days of hospitalization, TAU patients presented a mean value of 8 days during 1 year after treatment, 90 days after 5 years and 105 days after 8 years compared to INT patients with 1.2 days after 1 year, 19 days after 5 years and 35 days after 8 years. The comparison after 1 year was close to significant, the other ones were clearly significant favoring again the INT intervention.
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Background: Relapse prevention is a major aim of any treatment for schizophrenia patients. In general, recent meta-analyses showed that one third of schizophrenia patients relapse in the first year after treatment, which corresponds with rehospitalization. Since years, study data support evidence for successful relapse prevention of psycho-educative and family therapy approaches in combination with pharmacological treatment. So far little is known about the impact of Cognitive Remediation Therapy (CRT) on relapse prevention. Methods: The purpose of this RCT was to investigate whether additional CRT could prevent relapses compared to treatment as usual (TAU) defined as pharmacological and other psychosocial treatments. The CRT approach of choice was the Integrated Neurocognitive Therapy (INT) developed in our lab. INT is a group approach consisting of 4 modules including interventions on all the neuro-and social cognitive domains, defined by the MATRICS initiative, as well as educational, emotion regulation and stress reduction tasks. In this international multicenter study, a total of 156 stabilized schizophrenia outpatients, diagnosed with DSM-IV, participated. From this sample, 71 participants of two out of eight centers could be observed during a follow-up of 1, 5 and 8 years, regarding number of relapses and days of rehospitalization. Relapses were defined as increased symptoms followed by rehospitalization. Results: One year after therapy, no marked differences between INT and TAU groups in relapse rates were evident. But during 5-and 8-year follow-up, 78% and 83% of TAU patients relapsed compared to 48% and 52% of INT patients suggesting a significant benefit of INT. TAU patients suffered from more than 2 relapses after 5 years and 2.5 relapses after 8 years. In comparison, INT patients showed 0.9 relapses after 5 and 1.4 relapses after 8 years. After the 5 years follow-up there was a highly significant difference between INT and TAU, and after the 8-years a statistical tendency favoring INT could be found. Regarding the days of hospitalization, TAU patients presented a mean value of 8 days during 1 year after treatment, 90 days after 5 years and 105 days after 8 years compared to INT patients with 1.2 days after 1 year, 19 days after 5 years and 35 days after 8 years. The comparison after 1 year was close to significant, the other ones were clearly significant favoring again the INT intervention. Patients who completed this study were eligible to enroll in a 2-year, openlabel (OL), flexible-dose (20-80 mg/d) extension study in which patients were continued on lurasidone, or switched from placebo to lurasidone. These data are the results of an interim analysis of the 2-year study. Effectiveness measures included the Positive and Negative Syndrome Scale (PANSS) total score (responder criteria, ≥20% reduction from double-blind baseline).
Results: A total of 271 patients completed 6 weeks of double-blind treatment and entered the 2-year extension study. At the time of the interim analysis, 132 patients had completed 52 weeks of treatment (24 patients were 2-year study completers; 96 patients were still ongoing; and 12 patients had discontinued after 52 weeks); 57 patients were still ongoing in the first 1-year of treatment; and 82 patients terminated prior to week 52 (28 patients due to withdrawal of consent; 23 due to adverse events; 9 due to lack of efficacy; and 22 for other reasons). Mean PANSS total score at double-blind baseline was 93.5. Overall mean change from double-blind to open-label baseline (after 6 weeks of treatment) was -17.5 (for patients assigned to lurasidone vs. placebo in the initial 6-week study, mean change was: -19.8 vs. -12.9). Overall mean change from double-blind baseline in the PANSS total score at weeks 28 (n=215), 52 (n=133), 76 (n=86), and 104 (n=24) was -29.2, -34.0, -35.0, and -34.1, respectively. Responder rates at week 52 and week 104 were 91.7% and 100%, respectively. During open-label treatment, the most common adverse events were headache (21.8%), nausea (11.8%), and anxiety (11.8%); 6.6% of patients reported an adverse event as severe. Median change in laboratory parameters from double-blind baseline to weeks 52 and 104, respectively, were: total cholesterol, -2.0 and -5.0 mg/dL; triglycerides, +3.5 and +3.0 mg/dL; hemoglobin A1c, 0.0 and 0.1%; prolactin in female, +0.5 and -0.5 ng/mL and males, +0.15 and +3.5 ng/mL; and mean change from DB baseline in weight at weeks 52 and 104 were 3.8 and 7.2 kg, vs. an expected weight gain of 3.3 and 5.1 kg, based on the gender-and-age specific CDC growth chart. Discussion: In adolescents with schizophrenia, long-term treatment with lurasidone was associated with continued improvement in symptoms of schizophrenia. After one year of lurasidone treatment, minimal effects were observed on body weight, lipids, and glycemic indices. 
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